期刊文献+

葡萄糖耐量减低人群血小板相关功能研究 被引量:1

Platelet function in subjects with impaired glucose tolerance
原文传递
导出
摘要 目的探讨糖耐量减低(IGT)人群血小板活化状态及影响因素。方法选择IGT组33例、糖尿病组和正常对照组各30例为研究对象。采用流式细胞术(FCM)检测血小板膜蛋白CD62P、血小板激活复合物(PAC-1)阳性率和平均荧光强度(MFI);电阻抗法测定血小板数目(count)、血小板平均体积(MPV)、血小板分布宽度(PDW)及大血小板比率(P-LCR)等参数及总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、极低密度脂蛋白胆固醇(VLDL-C)、空腹血糖(FPG)和空腹胰岛素(FIns)。结果IGT组、糖尿病组CD62P%(P<0.01)、CD62PMFI(P<0.05)、PAC-1%(P<0.01)、MPV(P<0.05)、PDW(P<0.05)及P-LCR%(P<0.05)均较正常对照组升高;IGT组与糖尿病组之间差异无统计学意义(P>0.05)。多元回归分析显示,IGT组与CD62P密切相关的因素依次为P-LCR、LDL-C、TC和体质量指数(BMI);与PAC-1相关的因素依次为P-LCR、MPV及DBP。结论IGT人群存在与糖尿病同等程度的血小板活化;LDL-C、TC、DBP及BMI是影响血小板活化的因素。 Objective To investigate the state of platelet activation and its influencing factors in subjects with impaired glucose tolerance(IGT).Methods 33 patients with IGT were enrolled in this study.30 DM and healthy persons served as the controls.Percentage and mean fluorescence intensity of CD62P,PAC-1 as indexes of platelet activation were measured using whole blood flow cytometry(FCM).Changes of count of blood platelet,mean platelet volume(MPV),platelet distribution width(PDW) and platelet-large cell ratio(P-LCR)were analyzed with a blood cell counter.TC,TG,HDL-C,LDL-C,VLDL-C,FPG and FIns were simultaneously measured.Results IGT and subjects with diabetes had higher levels of CD62P%(P〈0.01) and CD62MFI(P〈0.05) and PAC-1%(P〈0.01) compared with the NC group.CD62P%,CD62MFI and PAC-1% had no statistical differences between the IGT and DM groups(P〉0.05).By stepwise regression analysis,CD62P in the IGT group had relation to P-LCR,LDL-C,TC and body mass index(BMI) independently.P-LCR,MPV and DBP were contri-butors to PAC-1.Conclusion There is the same degree of platelet activation in subjects with IGT,and DM.LDL-C,TC,DBP and BMI are contributors to CD62P and PAC-1 expressions on platelet in IGT.
出处 《山东大学学报(医学版)》 CAS 北大核心 2009年第11期9-13,共5页 Journal of Shandong University:Health Sciences
基金 泰安市科技发展计划项目(200083016)
关键词 糖耐量减低 CD62P 血小板激活复合物-1 流式细胞术 Impaired glucose tolerance CD62P Platelet activated complex-1 Flow cytometry
  • 相关文献

参考文献18

  • 1H u F B, Stampfer M J, Hatther S M, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes[J]. Diabetes Care, 2002, 25(7):1142-1148.
  • 2Cohwel J A, Nesto R W. The platelet in diabetes: focus on preventionof ischemic events [ J ]. Diabetes Care, 2003, 26 (7) :2181-2188.
  • 3Biondi Zoccai G G, Abbate A, Liuzzo G, et al. Atherothrombosis, inflammation, and diabetes[ J]. J Am Con Cardiot, 2003, 41(7) : 1071-1077.
  • 4Alberti K G, Zimmet P Z. Definition, diagnosis, and classification of diabetes mellims and complications, report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus[J]. Diabet med, 1999, 16(5):442-443.
  • 5Schafer A, Widder J, Eigenthalet M, et al. Increased platelet activation in young Zucker rats With impaired glucose tolerance is improved by acarbose[J]. Thromb Haemost, 2004, 92:97-103.
  • 6张栩,赵家军,于文.糖耐量减低患者颈动脉内膜中层厚度与血小板活化的关系[J].中国临床医学,2005,12(2):304-306. 被引量:2
  • 7Verice E, Jannuel C, Carreras M, et al. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status [ J ]. Diabetes, 2004, 53(4) : 1046-1051.
  • 8Anqiolillo D J, Femandez-Ortiz A, Bemardo E, et al. Platelet function profdes in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment [J]. Diabetes, 2005, 54(8):2430-2435.
  • 9Nofer J R, Walter M, Kehrel B, et al. HDl_3-mediated inhibition of thrombin Induced platelet aggregation and fibrinogen binding occurs via decreased Production of phosphoinositide-derived second messengers 1,2-Diacylglycerol and inositol 1,4,5- tris-phosphate [ J]. Arteriosclerosis Thromb Vasc Biol, 1998, 18(6) :861-869.
  • 10Galle J E, Bassenge R. Oxidized low density lipoprotein potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle[ J]. Cir Res, 1990, 66(3): 1287-1293.

二级参考文献28

  • 1丁振华.低密度脂蛋白氧化修饰的研究[J].生理科学进展,1994,25(1):67-69. 被引量:8
  • 2West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med,1995,16:333(20): 1 301 - 1 307.?A
  • 3Aviram M, Osamash H, Mira R. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMGCoA reduetase inhibitor therapy. J Cardiovasc Pharmcol, 1998, 31: 34839- 34 845.?A
  • 4Schultheiss HP, Tschoepe D, Esser J, et al. Large platelets continue: to circuliate in an activated state after myocardial infarction. Ecur J Clin Invest, 1994,24(4): 243.?A
  • 5Peerschke EB. Adhesive protein expression on thrombinstimulated platelets:time- dependent modulation of antifibrinogen, fibronectin and von Willebrand factor antibody binging. Blood, 1992,79:948.?A
  • 6LiPid Research Clinics Program. The lipids clinics coronary primary provention trial results the relationship of reduction in incidence of coronary heart disease to cholesterol lowing. JAMA, 1984,251:356-374.?A
  • 7Galle JE, Bassenge R. Oxidized low density lipoprotein potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Cir Res,1990,66:1 287-1 293.?A
  • 8Horio T, Kohno M, Murukawa K, et al. Increased plasma immunoreactive endothelin concentration in hypercholesterolemic rats. Atherosclerosis,1999,89:239.?A
  • 9Tschoepe D, Driesch E, Schwippert B, et al. Activated platelets in subjects at increased risk of IDDM. Diabetologia,1997,40(5):573 - 577.
  • 10Barro SE, Stration PD, Benjamin N. Reduction of LDL cholesterol by pravastatin does not influence platelet, activation in patient with wild hypercholesterolaemia at risk of coronary heart disease. Br J Clin Pharmacol,1991,32:127 - 129.?A?A

共引文献3070

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部